目的 探讨使用维利西呱对射血分数轻度降低心力衰竭（HFmrEF）患者的治疗效果。方法 选取武警新疆总队医院内一科2023-03至2024-06收治的HFmrEF患者80例,随机分为观察组、对照组,每组40例。对照组给予标准治疗,观察组在对照组治疗的基础上加用维利西呱片,随访6个月,比较NT-proBNP、LVEF、LAD、LVESD、LVEDD、6MWD及明尼苏达心力衰竭生活质量问卷（MLHFQ） 评分。比较两组高敏C反应蛋白（hs-CRP）、白介素6（IL-6）水平,并观察心力衰竭加重再入院发生率。结果 治疗后,与对照组比较,观察组NT-proBNP、hs-CRP、IL-6水平明显降低（P<0.05）, 两组LVESD、LVEDD降低,LVEF升高,MLHFQ 评分降低,6MWD明显延长（P<0.05）,患者生活质量改善,观察组心功能改善有效率高于对照组（95.0% vs. 77.5%,P<0.05）,两组不良反应差异无统计学意义（12.5% vs.5%,P=0.235）。结论 维利西呱治疗HFmrEF 患者能减轻炎性反应,改善NT-proBNP、LVESD 、LVEDD、 LVEF、6MWD等心功能指标,有效缓解临床症状。
Abstract
Objective To explore the therapeutic effect of Vericiguat on patients with heart failure with reduced ejection fraction (HFmrEF). Methods A total of 80 HFmrEF patients admitted to Xinjiang Uygur Autonomous Regional Corps Hospital of Chinese People's Armed Police Force from March 2023 to June 2024 were selected and randomly divided into a control group and an observation group,with 40 cases in each group. The control group received standard treatment, while the observation group was treated with Vericiguat tablets on the basis of the control group,and both groups were followed up for 6 months. NT-proBNP, LVEF, LAD, LVESD, LVEDD, 6MWD and Minnesota Heart Failure Quality of Life Questionnaire (MLHFQ) scores were compared. The levels of hypersensitive C-rective protein （hs-CRP） and Interleukin 6 （IL-6） were compared between the two groups,and the incidence of heart failure aggravated readmission was observed. Results After treatment,compared with the control group, the levesl of NT-proBNP, hs-CRP and IL-6 in the observation group were significantly lower (P<0.05), and both groups showed a decrease in LVESD and LVEDD, an increase in LVEF, a decrease in MLHFQ score, and a significant extension of 6MWD (P<0.05). The quality of life of patients improved, and the effective rate of cardiac function improvement in the observation group was higher than that of the control group （95.0% vs.77.5%,P<0.05）. The difference in adverse reactions between the two groups （12.5% vs.5%, P=0.235） was not statistically significant. Conclusions Vericiguat treatment for HFmrEF patients can reduce inflammation, improve NT-proBNP, LVESD, LVEDD, LVEF,and 6MWD, and effectively alleviate clinical symptoms.
关键词
射血分数轻度降低心力衰竭 /
维利西呱 /
炎性因子
Key words
heart failure with mildly reduced ejection fraction /
Vericiguat /
inflammatory factor
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail,2019, 21(11):1329-1337.
[2] Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis[J]. Circ Heart Fail, 2021, 14(10):e008406.
[3] McDonald M, Virani S, Chan M, et al.CCS/CHFS heart failure guidelines update defining a new pharmacologic standard of care for heart failure with reduced ejection fraction[J].Can J Cardio, 2021,37(4):531-546.
[4] Kosiborod M N, Jhund P S, Docherty K F, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPT HF trail[J]. Circulation ,2020,141(2):90-99.
[5] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等.中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志, 2024,52(3):235-275.
[6] Armstrong P W, Pieske B, Anstrom K J, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2020,382(20):1883-1893.
[7] 陈灏珠, 钟南山, 陆再英. 内科学[M]. 北京:人民卫生出版社,2018:196.
[8] Mcdonagh T A, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[9] Rastogi A, Novak E, Platts A E, ,et al. Epidemiology. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction[J]. Eur J Heart Fail, 2017, 19(12):1597-1605.
[10] Armstrong P W, Roessig L, Patel M J, et al.A multicenter randomized,double- blind, placebo -controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator:the VICTOTIA trial[J].JACC-Heart Fail,2018,6(2):96-104.
[11] Hulot J S, Trochu J N, Donal E, et al.Vericiguat for the treatment of heart failure:mechanism of action and pharmacological properties compared with other emerging therapeutic option[J].Expert Opin Pharmaco,2021,22(14):1847-1855.
[12] Kaplinsky E, Perrone S, Barbagelata A.Emerging concepts inheart failure management and treatment:focus on vericiguat[J]. Drugs Context,2023,36(12):2022-2025.
[13] 贾晓艳,安晋阳,彭可玲,等.可溶性鸟苷酸环化酶激动剂治疗心力衰竭疗效和安全性的网状Meta分析[J].中国新药与临床杂志,2023,42(1) : 48-57.
[14] 徐文,陈朝聪,徐文娟.复方丹参滴丸联合坎地沙坦酯片对老年慢性心力衰竭患者的临床疗效[J].中成药, 2023, 45(8): 2797-2800.
[15] 王亚鑫,黄毕,郭永正,等. 维利西呱在心力衰竭中应用进展[J].重庆医科大学学报,2024,49(4):354-359.
[16] Markham A, Duggan S.Vericiguat:first approval[J]. Drugs,2021,81(6):721-726.
[17] Nair N.Epidemiology and pathogenesis of heart failure with preserved ejection fraction[J]. Rev Cardiovasc Med, 2020,21(4): 531-540.
[18] 张存新,陈俊华. 沙库巴曲缬沙坦治疗原发性高血压并射血分数保留心功能衰竭的疗效[J].武警医学, 2020, 31(12):1017-1020.
[19] 崔莹,杨绍兵,杨文娟. 维利西呱联合沙库巴曲缬沙坦对心力衰竭患者心功能及血液流变学的影响[J]. 临床合理用药, 2024, 17(18):14-16.
[20] Emdin M, Aimo A,Castiglione V,et al.Targeting cyclic guanosine monophosphate to treat heart failure:JACC review topic of the week[J]. J Am Coll Cardiol,2020,76(15):1795-1807.
[21] 乔芳,石伦光,李丽娟,等. 哮喘合并心力衰竭患者血清cTnI,CK-MB,hs-CRP 及SAA 水平变化及其临床意义[J].中国实验诊断学,2022,26(5):671-675.
[22] 徐万忠,白艳丽,王晓麒. 白细胞介素基因多态性对老年严重心力衰竭患者预后的预测作用[J].中华老年心脑血管病杂志, 2020, 22(7):722-724.
PDF(2455 KB)
